Clinical Trial Update: A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL [Phase 3]

View source ↗

Summary

Phase 3 single-arm trial assessing pralatrexate for relapsed or refractory peripheral T-cell lymphoma completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Pralatrexate (pralatrexate)

Snippet

Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd | Conditions: Refractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2019-09-12